We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Global Hospital Acquired Infections Testing Kits Market to Reach USD 1.8 Billion by 2026

By LabMedica International staff writers
Posted on 08 Apr 2022

The global hospital acquired infections testing kits market is expected to grow at a CAGR of 12. More...

7% from USD 1.12 billion in 2021 to USD 1.27 billion in 2022 and is projected to grow further at a CAGR of 8.8% to USD 1.78 billion in 2026, driven by increased incidence of chronic diseases. The rates of hospital acquired infection are higher among patients with increased susceptibility due to old age and underlying chronic diseases, such as COVID-19.

These are the latest findings of The Business Research Company (London, UK), a market intelligence firm.

The unprecedented coronavirus outbreak has caused a surge in the demand for hospital acquired infections testing kits, due to the rise in hospital acquired infections during the pandemic. The pandemic has raised enormous concerns over the quality of care in hospitals, due to the rising number of patients during COVID-19 and the change in staffing numbers. Multiple hospitals have experienced an increase in staffing levels, with traveling nurses reporting that these nurses were unfamiliar with hospital infection control processes. Such circumstances have made it difficult for hospitals to maintain patient safety and quality of care.

Increasing healthcare expenditure is predicted to drive a surge in the demand for hospital acquired infections testing kits. The growth in healthcare expenditure is aiding governments and organizations to spend more on prescription drugs, hospitals, and physical & clinical services, thereby driving the hospital acquired infections testing kits market. Consequently, the rise in healthcare spending will continue to drive an increase in the demand for hospital acquired infections testing kits in the near future.

Geographically, North America held the largest share of 36.2% of the global hospital acquired infections testing kits market in 2021, followed by the Asia-Pacific and other regions. Going forward, South America, Africa and the Middle East will be the world’s fastest-growing markets for hospital acquired infections testing kits with a CAGR of 9.3%, 8.8% and 8.8%, respectively, followed by the Asia Pacific and Western Europe.

Related Links:
The Business Research Company 


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.